Stockreport

NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO

NovaBridge Biosciences - American Depositary Shares  (NBP) 
PDF Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class [Read more]